The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Patients with and without obesity experienced significant pain reductions and improved functioning following telerehabilitation for chronic musculoskeletal pain.

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

By studying the Sun’s acoustic waves, scientists are uncovering its hidden dynamics, refining stellar models, and influencing ...

Cebranopadol reduced pain intensity in patients following abdominoplasty surgery in the ALLEVIATE-1 clinical trial.

If you live long enough in one place, you witness the grand saga of a city’s history unfold. Burwood Council recently ...

Music has the best chance of providing pain relief when it is played at our natural rhythm, a McGill University research team ...

Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.